Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	137.88	108.97	115.67	337	171.89
Short-Term Investments	116.59	231.74	114.45	102.95	118.96
Cash & Cash Equivalents	254.47	340.71	230.12	439.95	290.85
Cash Growth	-25.31%	48.06%	-47.69%	51.27%	64.75%
Receivables	27.66	11.34	3.35	1.83	0
Inventory	45.58	18.33	10.15	5.88	0
Other Current Assets	11.16	4.36	2.5	2.35	5.76
Total Current Assets	338.87	374.73	246.12	450	296.6
Property, Plant & Equipment	90.21	59.42	69	47.13	41.29
Long-Term Investments	6	6.05	0	0	0
Goodwill and Intangibles	9.27	112.52	202.3	218.31	0
Other Long-Term Assets	34.12	29.19	13.75	4.78	2.4
Total Long-Term Assets	139.59	207.17	285.05	270.22	43.69
Total Assets	478.45	581.9	531.16	720.22	340.29
Accounts Payable	13.55	4.55	10.6	12.66	8.01
Deferred Revenue	81.16	85.44	83.51	85.15	55.86
Current Debt	10.85	4.91	4.75	4.44	3.47
Other Current Liabilities	-16.34	-19.22	-31.57	-41.28	-26.36
Total Current Liabilities	89.22	75.68	67.29	60.96	40.98
Long-Term Debt	467.58	413.56	319.77	207.67	25.87
Other Long-Term Liabilities	73.25	80.06	75.64	77.29	47.95
Total Long-Term Liabilities	540.83	493.62	395.4	284.97	73.82
Total Liabilities	630.06	569.3	462.69	345.93	114.8
Total Debt	478.43	418.47	324.51	212.11	29.34
Debt Growth	14.33%	28.95%	52.99%	622.93%	-
Retained Earnings	-2,078.36	-1,754.37	-1,397.95	-1,126.29	-844.2
Comprehensive Income	0.01	-0.37	-0.02	0	0
Shareholders' Equity	-151.6	12.6	68.47	374.29	225.49
Net Cash / Debt	-223.97	-77.76	-94.4	227.84	261.51
Net Cash / Debt Growth	-	-	-	-12.87%	48.13%
Net Cash Per Share	-2.65	-1.07	-1.40	3.93	6.02
Working Capital	249.64	299.05	178.83	389.04	255.62
Book Value Per Share	-1.79	0.17	1.01	6.45	5.19

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).